Showing 3401-3410 of 19337 results for "".
Routes Reconsidered: A Case-Based Debate in SERD Selection
https://reachmd.com/programs/cme/routes-reconsidered-a-case-based-debate-in-serd-selection/39807/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.The Road Ahead: What's on the Horizon for FCS and SHTG Management
https://reachmd.com/programs/cme/the-road-ahead-whats-on-the-horizon-for-fcs-and-shtg-management/33228/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.SHTG: Defining the Unmet Clinical Need
https://reachmd.com/programs/cme/shtg-defining-the-unmet-clinical-need/33224/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
https://reachmd.com/programs/cme/setting-the-bar-guideline-recommended-treatment-in-hypertriglyceridemia/33221/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.From Data to Debate: Global Perspectives on HR+/HER2- mBC Care
https://reachmd.com/programs/cme/from-data-to-debate-global-perspectives-on-hrher2-mbc-care/37268/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Unmet Needs in Endocrine Therapy: Rethinking the HR+/HER2- mBC Treatment Roadmap
https://reachmd.com/programs/cme/unmet-needs-in-endocrine-therapy-rethinking-the-hrher2-mbc-treatment-roadmap/39797/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
https://reachmd.com/programs/cme/beyond-fulvestrant-oral-serds-redefining-er-targeting/39800/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.SHTG: Decoding the Latest Clinical Trial Outcomes
https://reachmd.com/programs/cme/shtg-decoding-the-latest-clinical-trial-outcomes/33225/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.Latest Clinical Trial Outcomes and Breakthroughs for FCS
https://reachmd.com/programs/cme/latest-clinical-trial-outcomes-and-breakthroughs-for-fcs/33223/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.The Fifth Pillar? Closing the Gap in HFrEF
https://reachmd.com/programs/cme/the-fifth-pillar-closing-the-gap-in-hfref/37615/Experts discuss emerging heart failure data, outline clinical significance, and address patient care needs, featuring insights presented at HFSA 2025.